Confined or spread disease-Spread with distant metastasis Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread with distant metastasis Posts on Medivizor

Can CEA levels predict tumor response to treatment in advanced colorectal cancer?

Posted by on Feb 12, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the relationship between changes in the levels of carcinoembryonic antigen (CEA) and colorectal cancer response to treatment. Researchers suggested that CEA levels are associated with tumor response and can be used as a prognostic factor. Some background In 2014 the European Society for Medical Oncology...

Read More

Regorafenib followed by cetuximab is associated with longer survival in the treatment of advanced colorectal cancer

Posted by on Jan 29, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of treatment with regorafenib (Stivarga) followed by cetuximab (Erbitux) in the treatment of advanced colorectal cancer. Researchers suggested that this treatment improves survival of these patients. Some background New treatments have become available in the past 20 years to treat...

Read More

Hypofractionated stereotactic radiotherapy improves outcomes in advanced colorectal cancer

Posted by on Jan 20, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of hypofractionated stereotactic radiotherapy (HSR; high doses of radiation given in fewer sessions than conventional radiotherapy) in advanced colorectal cancer. Researchers suggested that HSR is associated with improved outcomes and manageable side effects. Some background Colorectal cancer is...

Read More

Treating BRCA1/2 mutated breast cancer that has spread with lurbinectedin

Posted by on Dec 27, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out how well lurbinectedin (PM01183) works in treatment of breast cancer with BRCA1/2 mutations (abnormal genes), which has spread. The study found that lurbinectedin worked well in treating patients with BRCA1/2 mutated breast cancer which had spread. Some background BRCA1 and BRCA2 are genes that stop tumors...

Read More

Treating BRCA1/2 mutated breast cancer that has spread with lurbinectedin

Posted by on Dec 27, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out how well lurbinectedin (PM01183) works in treatment of breast cancer with BRCA1/2 mutations (abnormal genes), which has spread. The study found that lurbinectedin worked well in treating patients with BRCA1/2 mutated breast cancer which had spread. Some background BRCA1 and BRCA2 are genes that stop tumors...

Read More

Thyroid hormones ratio can predict outcomes in patients with advanced colorectal cancer

Posted by on Dec 8, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the impact of the thyroid hormones (TH) on survival outcomes of patients with colorectal cancer treated with regorafenib (Stivarga). Researchers suggested that TH ratio can predict the outcomes in these patients. Some background TH such as FT3 (free triiodothyronine) and FT4 (free thyroxine) are released...

Read More

Predictive factors for the treatment of metastatic colorectal cancer with panitumumab

Posted by on Dec 5, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of panitumumab (Vectibix) and the predictive factors for the treatment of metastatic (spread to other parts of the body) colorectal cancer. Researchers suggested that this treatment was effective for these patients and that early tumor shrinkage and RAS mutation (permanent change) are...

Read More

Is regorafenib a safe option for the treatment of metastatic colorectal cancer?

Posted by on Nov 22, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients. Some background The standard treatment...

Read More

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Posted by on Nov 11, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well two medications worked in treating advanced triple negative breast cancer, atezolizumab (Tecentriq) and nab-paclitaxcel (Abraxane).  The study found that using these two medications together improved survival in these patients. Some background Triple-negative breast cancer (TNBC) is breast cancer...

Read More

Metronomic chemotherapy for HR+ advanced breast cancer

Posted by on Nov 7, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well using metronomic chemotherapy with capecitabine (Xeloda) combined with aromatase inhibitors works for patients with hormone receptor positive advanced breast cancer. The study found that this treatment works well and is safe, and therefore should be considered as a potential treatment option. Some...

Read More